Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

AcGlcAs: A Novel P53-Targeting Arsenical with Potent Cellular Uptake and Cancer Cell Selectivity

9 Dec 2023

Abstract excerpt

Arsenic trioxide (ATO) targets PML/RARα and leads to miraculous success in treating acute promyelocytic leukemia. Notably, ATO also targets p53, the most frequently mutated protein in cancers, through a similar binding mechanism. However, p53-targeting ATO trials are challenging due to the poor cellular uptake and cancer selectivity of ATO. Here, we analyzed the structure-activity relationship of arsenicals and...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Acute Myeloid Leukemia Research
Share to Advanced biosensing and bioanalysis techniques
Share to Retinoids in leukemia and cellular processes

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 38069817
DOI: 10.1021/acs.jmedchem.3c00104

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 8 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

AcGlcAs: A Novel P53-Targeting Arsenical with Potent Cellular Uptake and Cancer Cell SelectivityPMID 38069817Read ↗

Arsenic Trioxide Rescues Structural p53 Mutations through a Cryptic Allosteric Site.Semantic proximity Read ↗

Molecular Targets of Arsenic Trioxide in Malignant CellsSemantic proximity Read ↗

Targeting mutant p53 with arsenic trioxide: A preclinical study focusing on triple negative breast cancerSemantic proximity Read ↗

Diverse rescue potencies of p53 mutations to ATO are predetermined by intrinsic mutational properties.Semantic proximity Read ↗

Pro-ATO/Allicin Liposomes for Dual-Pathway Targeting of p53-Mutant Tumors.Semantic proximity Read ↗

Arsenic and an Old Place: Rescuing p53 Mutants in Cancer.Semantic proximity Read ↗

Broad-spectrum rescue compounds for structural p53 mutations: perspective on 'Arsenic trioxide rescues structural p53 mutations through a cryptic allosteric site'.Semantic proximity Read ↗

The genomic landscape of sensitivity to arsenic trioxide uncovered by genome-wide CRISPR-Cas9 screeningSemantic proximity Read ↗

Arsenic trioxide controls the fate of the PML-RARalpha oncoprotein by directly binding PML.Semantic proximity Read ↗

Arsenoplatin-1 Is a Dual Pharmacophore Anticancer AgentSemantic proximity Read ↗

Synergistic Dual Targeting of Thioredoxin and Glutathione Systems Irrespective of p53 in Glioblastoma Stem Cells<strong> </strong>Semantic proximity Read ↗

Arsenic trioxide extends survival of Li-Fraumeni syndrome mimicking mouse.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.